From Sanofi’s 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 3D: 10577
Compulsory licensing of patents: 43
3D. Risk Factors
From Novartis’ 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 3D: 10297
Compulsory licensing of patents: 55
Earthquake risk: 96
3.D Risk Factors
From GlaxoSmithKline’s 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012. Number of words in Item 3D: 6304 Compulsory licensing of patents: 42 3.D Risk factors Principal risk factors and uncertainties There are risks and uncertainties… Continue Reading
From Bristol Myers Squibb’s 10-K report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item A1: 3605
Compulsory licensing of patents: 27
Item 1A. RISK FACTORS.
From Merck’s 10-K report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 1A: 8038
Compulsory licenses: 44
Item 1A.Risk Factors.
From AbbVie’s 10-K report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 1A: 11,093
Compulsory licensing of patents: 88
ITEM 1A. RISK FACTORS
From Pfizer’s 10-K report, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item A1: 7790
Compulsory licensing of patents: 63
Counterfeit products: 126
Pricing Pressures and Government Regulation: 604
Foreign Exchange and Interest Rate Risk: 324
Global Economic Conditions: 382
Prohibition against the use of federal funds for reimbursement of erectile dysfunction medications: 50
On 9 December 2013, six members of Congress sent a letter to President Obama citing concerns in the TPP regarding access to health care and affordable medicines. The six members include Representatives Jan Schakowsky (D-IL), Michael Michaud (D-ME), Rosa DeLauro (D-CT), George Miller (D-CA), Barbara Lee (D-CA) and Peter Welch (D-MA). The letter primarily addresses efforts by USTR that result in greater monopoly power and delay entry of generic medicines, and how such efforts will affect state and federal budgets. Continue Reading
Professor Joseph Stiglitz has written an open letter to the TPP negotiators, asking that they resist proposals to weaken consumer rights in intellectual property. The letter identifies 12 specific “grave risks” in the IP Chapter, and calls upon negotiators to publish the investor state dispute resolution text.
The WHO is considering potential projects that will demonstrate the feasibility and benefits of open innovation models, delinkage of R&D costs and product prices, and innovative finance mechanisms. The process for selection began at the regional level, as each of six WHO regions was allowed to shortlist four projects that will be considered at a December 3-4, 2013 meeting of experts in Geneva, where the list will be narrowed again, and then considered by the WHO Executive Board in January 2014 and the WHO World Health Assembly in May 2014. Continue Reading